Lineage Cell Therapeutics (LCTX) Short-term Investments (2017 - 2026)

Lineage Cell Therapeutics' Short-term Investments history runs 10 years deep, the most recent figure standing at $17.4 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 91700.0% year-over-year to $17.4 million in Q1 2026; TTM through Mar 2026 was $17.4 million, a 91700.0% increase from a year earlier, with the FY2025 full-year figure at $15.0 million, up 643.55% from the prior year.
• Short-term Investments grew to $17.4 million in Q1 2026 per LCTX's latest filing, from $15.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $46.5 million in Q4 2022 and bottomed at $17000.0 in Q2 2025.
• The 5-year median for Short-term Investments is $5.0 million (2024), against an average of $11.3 million.
• Across the five-year window, Short-term Investments plunged 99.89% in 2023 and jumped 91700.0% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $46.5 million in 2022, then plunged by 99.89% to $50000.0 in 2023, then surged by 3932.0% to $2.0 million in 2024, then jumped by 643.55% to $15.0 million in 2025, then advanced by 16.36% to $17.4 million in 2026.
• Per Business Quant, the three latest LCTX Short-term Investments figures stand at $17.4 million (Q1 2026), $15.0 million (Q4 2025), and $23000.0 (Q3 2025).